Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors

Basit Öğe Kaydı
dc.contributor.authorErgun, Yakup
dc.contributor.authorEsen, Selin Akturk
dc.contributor.authorBardakci, Murat
dc.contributor.authorUcar, Gokhan
dc.contributor.authorKalkan, Ziya
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorSeyran, Erdogan
dc.date.accessioned2024-04-24T17:20:43Z
dc.date.available2024-04-24T17:20:43Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractBACKGROUND: The relationship of the ABO blood group system with the immune response is known, but its relationship with immune checkpoint inhibitors (ICIs) has not been clearly investigated until now. OBJECTIVE: In this study, the relationship between different blood groups and nivolumab treatment response in patients with advanced malignant melanoma was investigated. METHODS: The data of patients who used nivolumab for advanced malignant melanoma between April 2018 and April 2021 were retrospectively reviewed. RESULTS: A total of 73 patients were included in the study. In the progression-free survival (PFS) analysis according to blood groups, it was 3.9 months, 16.1 months, 20.0 months and 3.0 months for A, B, AB and O, respectively ( p = 0.1). Overall survival (OS) analysis according to blood groups was 5.1 months, 25.0 months, 20.0 months and 9.3 months for A, B, AB and O, respectively (p = 0.1). The B antigen group (B or AB) had significantly longer PFS and OS than the non-B antigen group (A or O) (16.1 vs. 3.5 months for PFS, respectively, p = 0.03; 20.0 vs. 7.4 months for OS, respectively, p = 0.02). CONCLUSIONS: The presence of B antigen provides a significant advantage in terms of survival in patients using ICIs for advanced melanoma.en_US
dc.description.sponsorship[E1-21-1799]en_US
dc.description.sponsorshipThis study was approved by our Institutional Ethics Committee and was conducted according to the principles of the Declaration of Helsinki. (Decision Date: 26/05/2021 Decision No: E1-21-1799).en_US
dc.identifier.doi10.3233/CBM-210455
dc.identifier.endpage336en_US
dc.identifier.issn1574-0153
dc.identifier.issn1875-8592
dc.identifier.issue2en_US
dc.identifier.pmid35001878
dc.identifier.scopus2-s2.0-85130904660
dc.identifier.scopusqualityQ2
dc.identifier.startpage329en_US
dc.identifier.urihttps://doi.org/10.3233/CBM-210455
dc.identifier.urihttps://hdl.handle.net/11468/19213
dc.identifier.volume34en_US
dc.identifier.wosWOS:000800580800014
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherIos Pressen_US
dc.relation.ispartofCancer Biomarkers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectNivolumaben_US
dc.subjectAbo Blood Groupen_US
dc.subjectPredictiveen_US
dc.subjectBiomarkeren_US
dc.titlePredictive and prognostic effect of ABO blood group on immune checkpoint inhibitorsen_US
dc.titlePredictive and prognostic effect of ABO blood group on immune checkpoint inhibitors
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu